Predictors of ACEI/ARB therapy in patients with hypertrophic cardiomyopathy : results of a national registry

• Autor(es): Martins, E. ; Lebreiro, A. ; Sousa, C. ; Leite, S. ; Sousa, A. ; Belo, A. ; Brito, Dulce ; Cardim, N.
• Data: 2018
• Identificador Persistente: http://hdl.handle.net/10451/40136
• Origem: Repositório da Universidade de Lisboa
• Assunto(s): Angiotensin-converting enzyme inhibitors; Hypertrophic cardiomyopathy
• Tipo de Documento: Artigo científico
• Idioma: Inglês
• Contribuidor(es): Repositório Científico de Acesso Aberto da ULisboa

Descrição

Introduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are not considered disease-modifying drugs in hypertrophic cardiomyopathy (HCM) and their use is usually dependent on other clinical indications. Few data exist about the use of ACEI/ARB in HC in the real world, particularly in patients with intraventricular obstruction. Objective: In this study, we sought to determine the frequency of ACEI / ARB therapy in patients with HCM and the predictors for their use.